Audit 402623

FY End
2025-12-31
Total Expended
$1.77M
Findings
0
Programs
7
Year: 2025 Accepted: 2026-05-29

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS $575,783 Yes 0
64.054 RESEARCH AND DEVELOPMENT $251,633 Yes 0
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $56,797 Yes 0
93.350 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES $29,946 Yes 0
93.866 AGING RESEARCH $12,066 Yes 0
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $9,958 Yes 0
93.837 CARDIOVASCULAR DISEASES RESEARCH $2,359 Yes 0

Contacts

Name Title Type
JXPVN9BZLZ15 Felix Oliver Auditee
2024626820 Tina Peacher Auditor
No contacts on file

Notes to SEFA

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Institute for Clinical Research, Inc. (“ICR”) under programs of the federal government for the year ended December 31, 2025. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of ICR, it is not intended to and does not present the financial position, changes in net assets, or cash flows of ICR.
Expenditures reported in the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein, certain types of expenses are not allowable or are limited to reimbursement.
ICR uses a provisional indirect cost rate of approximately 29% approved by the Department of Health and Human Services in accordance with the Uniform Guidance. ICR has elected not to use the de minimis indirect cost rate allowed under the Uniform Guidance.